Debu Tripathy, CURE’s editor-in-chief, is in Chicago for the annual meeting of the American Society of Clinical Oncology.
A study announced at ASCO found that bone-strengthening drugs given for bone metastases in advanced breast cancer could be given less frequently. Patients who had received monthly Zometa for about a year were randomized to be given intravenous Zometa every three months or the standard monthly dose. Researchers found both groups of women had the same effect. Patients on the less frequent regimen also had slightly fewer complications.